

Lacrisert[®] (hydroxypropyl cellulose) – Drug Shortage

- The drug shortage of Lacrisert (hydroxypropyl cellulose) ophthalmic insert is ongoing. Lacrisert has • been unavailable for at least 90 days.
 - Per Bausch Health, Lacrisert is on back order due to manufacturing interruptions caused by the COVID-19 pandemic. Lacrisert may not be available until September 2020.
- Lacrisert is indicated in patients with moderate to severe dry eye syndromes, including • keratoconjunctivitis sicca. Lacrisert is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions.

| Product Description | NDC # |
|---|--------------|
| Lacrisert (hydroxypropyl cellulose) ophthalmic insert | 24208-800-60 |



optumrx.com

OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.